17 α-hydroxyprogesterone caproate (Makena™): In the prevention of preterm birth

Pediatric Drugs

Volumn 13, Issue 5, 2011, Pages 337-345

  Deeks, Emma D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Hydroxyprogesterone; Preterm birth

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; MAKENA; UNCLASSIFIED DRUG;

ARTICLE; BIRTH WEIGHT; BRAIN HEMORRHAGE; CONGENITAL MALFORMATION; CRYPTORCHISM; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENITAL MALFORMATION; GESTATIONAL AGE; HUMAN; INJECTION SITE CELLULITIS; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LUNG EMBOLISM; MATERNAL HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MICROPENIS; NECROTIZING ENTEROCOLITIS; NEUROLOGIC DISEASE; NONHUMAN; OLIGOHYDRAMNIOS; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TESTIS TORSION; TREATMENT OUTCOME; URTICARIA;

EID: 80052536426     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11208140-000000000-00000     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention. Premature birth [online]. Available from URL: http://www.cdc.gov/features/prematurebirth/ [Accessed 2011 Jun 3]
2. Dodd JM, Crowther CA. The role of progesterone in prevention of preterm birth. Int J Womens Health 2009; 1: 73-84
3. Institute of Medicine. Preterm birth: causes, consequences, and prevention [online]. Available from URL: Files/2006/Preterm-Birth-Causes- Consequences-and-Prevention/Preterm%20 Birth%202006%20Report%20Brief.pdf [Accessed 2011 Jun 3]
4. Armstrong J, Meis PJ. Clinical, family, and cost outcomes of preterm births: an overview of the problem and prevention opportunities. J Clin Outcomes Manage 2007 Oct; 14 (10): 547-53 (Pubitemid 350044369)
5. March of Dimes. Premature birth [online]. Available from URL: http:// www.marchofdimes.com/baby/premature-indepth.html [Accessed 2011 Jul 6]
6. Iams JD, Berghella V. Care for women with prior preterm birth. Am J Obstet Gynecol 2010 Aug; 203 (2): 89-100
7. How HY, Sibai BM. Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety. Ther Clin RiskManag 2009 Feb; 5 (1): 55-64
8. U.S. Food and Drug Administration. FDA approves drug to reduce risk of preterm birth in at-risk pregnant women [media release]. 2011 Feb 4 [online]. Available from URL:
9. Cohen AW, Copel JA, Macones GA, et al. Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of makena (17ahydroxyprogesterone caproate).Obstet Gynecol 2011 Jun; 117 (6): 1408-12
10. KV Pharmaceutical Co. and Ther-Rx Corporation. Makena- (hydroxyprogesterone caproate injection) for intramuscular use: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/021945s000lbl.pdf [Accessed 2011 May 23]
11. Meis PJ, Aleman A. Progesterone treatment to prevent preterm birth. Drugs 2004; 64 (21): 2463-74 (Pubitemid 39472632)
12. Challis JRG. Mechanism of parturition and preterm labor. Obstet Gynecol Surv 2000 Oct; 55 (10): 650-60
13. Whittle WL, Patel FA, Alfaidy N, et al. Glucocorticoid regulation of human and ovine parturition: the relationship between fetal hypothalamic- pituitary-adrenal axis activation and intrauterine prostaglandin production. Biol Reprod 2001 Apr; 64 (4): 1019-32 (Pubitemid 32239171)
14. Attardi BJ, Zeleznik A, Simhan H, et al. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. Am J Obstet Gynecol 2007 Dec; 197 (6): 599.e1-7
15. Sexton DJ, O'Reilly MW, Friel AM, et al. Functional effects of 17alphahydroxyprogesterone caproate (17P) on human myometrial contractility in vitro. Reprod Biol Endocrinol 2004 Dec 7; 2: 80
16. Anderson L, Martin W, Higgins C, et al. The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy. Reprod Sci 2009 Nov; 16 (11): 1052-61
17. Ruddock NK, Shi SQ, Jain S, et al. Progesterone, but not 17-alphahydroxyprogesterone caproate, inhibits humanmyometrial contractions. Am J Obstet Gynecol 2008 Oct; 199 (4): 391.e1-7
18. O'Brien JM, Ho SJ, Istwan NB, et al. Uterine activity in women receiving 17 α-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study. Am J Perinatol 2010 Feb; 27 (2): 157-62
19. Facchinetti F, Dante G, Venturini P, et al. 17α-hydroxy- progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery.Am J Perinatol 2008 Sep; 25 (8): 503-6
20. Facchinetti F, Paganelli S, Comitini G, et al. Cervical length changes during preterm cervical ripening: effects of 17-α-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007 May; 196 (5): 453.e1-4; discussion 421
21. Durnwald CP, Lynch CD, Walker H, et al. The effect of treatment with 17 alphα-hydroxyprogesterone caproate on changes in cervical length over time. Am J Obstet Gynecol 2009 Oct; 201 (4): 410.e1-5
22. Kuon RJ, Shi SQ, Maul H, et al. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle.AmJ Obstet Gynecol 2010May; 202 (5): 455.e1-9
23. Patel S, Li A, Goodwin TM, et al. Effect of 17-a hydroxyprogesterone caproate on the production of tumor necrosis factor-a and the expression of cyclooxygenase- 2 in lipopolysaccharide-treated gravid human myometrial explants. J Perinatol 2010 Sep; 30 (9): 584-9
24. Foglia LM, Ippolito DL, Stallings JD, et al. Intramuscular 17α-hydroxyprogesterone caproate administration attenuates immunoresponsiveness of maternal peripheral blood mononuclear cells. Am J Obstet Gynecol 2010 Dec; 203 (6): 561.e1-5
25. Amory J, Lawler R, Shields L. Hydroxyprogesterone caproate and progesterone increase tumor necrosis factor-alpha production in lipopolysaccharide stimulated whole blood from non-pregnant women. J Perinat Med 2005; 33 (6): 506-9 (Pubitemid 41769709)
26. Luo G, Abrahams VM, Tadesse S, et al. Progesterone inhibits basal and TNF-ainduced apoptosis in fetal membranes: a novel mechanism to explain progesterone- mediated prevention of preterm birth. Reprod Sci 2010 Jun; 17 (6): 532-9
27. Meis PJ, KlebanoffM, Thom E, et al. Prevention of recurrent preterm delivery by 17 alphα-hydroxyprogesterone caproate [published erratum appears in N Engl J Med 2003; 349 (13): 1299].NEngl J Med 2003 Jun 12; 348 (24): 2379-85
28. Klebanoff MA, Meis PJ, Dombrowski MP, et al. Salivary progesterone and estriol among pregnant women treated with 17-α-hydroxyprogesterone caproate or placebo. Am J Obstet Gynecol 2008 Nov; 199 (5): 506.e1-7
29. Johnson JWC, Lee PA, Zachary AS, et al. High-risk prematurity-progestin treatment and steroid studies. Obstet Gynecol 1979 Oct; 54 (4): 412-8 (Pubitemid 9247464)
30. Tiboni GM, Del Corso A, Marotta F. Progestational agents prevent preterm birth induced by a nitric oxide synthesis inhibitor in the mouse. In Vivo 2008 Jul-Aug; 22 (4): 447-50
31. Caritis SN, Sharma S, Zhang S, et al. Pharmacokinetics (PK) of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation [abstract no. 58]. 56th Annual Meeting of the Society for Gynecologic Investigation; 2009 Mar 17-21; Glasgow
32. Caritis SN, Sharma S, Zhang S, et al. Placental transfer of 17-alpha hydroxyprogesterone caproate (17-OHPC) [abstract no. 517]. 56th Annual Meeting of the Society for Gynecologic Investigation; 2009 March 17-21; Glasgow
33. Caritis SN, Sharma S, Venkataramanan R, et al. Pharmacokinetics of 17- hydroxyprogesterone caproate in multifetal gestation. Am J Obstet Gynecol 2011 Jul; 205: 40.e1-8
34. Onsrud M, Paus E, Haug E, et al. Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 1985; 64: 519-23 (Pubitemid 15241030)
35. Sharma S, Ellis ECS, Dorko K, et al. Metabolism of 17α- hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes. Drug Metab Dispos 2010 May; 38 (5): 723-7
36. Sharma S, Ou J, Strom S, et al. Identification of enzymes involved in the metabolism of 17α-hydroxyprogesterone caproate: an effective agent for prevention of preterm birth. Drug Metab Dispos 2008 Sep; 36 (9): 1896-902
37. Hemauer SJ, Yan R, Patrikeeva SL, et al. Transplacental transfer and metabolism of 17-α-hydroxyprogesterone caproate. Am J Obstet Gynecol 2008 Aug; 199 (2): 169.e1-5
38. Data on file. KV Pharmaceutical Co.
39. Meis PJ, Klebanoff M, Dombrowski MP, et al. Does progesterone treatment influence risk factors for recurrent preterm delivery? Obstet Gynecol 2005 Sep; 106 (3): 557-61 (Pubitemid 41208789)
40. Spong CY, Meis PJ, Thom EA, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol 2005 Sep; 193 (3 Pt 2): 1127-31 (Pubitemid 41285506)
41. Saghafi N, Khadem N, Mohajeri T, et al. Efficacy of 17α- hydroxyprogesterone caproate in prevention of preterm delivery. JObstet GynaecolRes. Epub 2011 May
42. Johnson JWC, Austin KL, Jones GS, et al. Efficacy of 17α- hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975 Oct 2; 293 (14): 675-80
43. Yemini M, Borenstein R, Dreazen E, et al. Prevention of premature labor by 17 α-hydroxyprogesterone caproate. Am J Obstet Gynecol 1985 Mar 1; 151 (5): 574-7 (Pubitemid 15049683)
44. Ibrahim M, Ramy ARM, Younis MAF. Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertil Soc J 2010; 15 (1): 39-41
45. Northen AT, Norman GS, Anderson K, et al. Follow-up of children exposed in utero to 17 α-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007 Oct; 110 (4): 865-72 (Pubitemid 47508752)
46. Rebarber A, Istwan NB, Russo-Stieglitz K, et al. Increased incidence of gestational diabetes in women receiving prophylactic 17α- hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 2007 Sep; 30 (9): 2277-80 (Pubitemid 47359031)
47. KV Pharmaceutical Company. Confirmatory study of 17P versus vehicle for the prevention of preterm birth in women with a previous singleton spontaneous preterm delivery [ClinicalTrials.gov identifier NCT01004029]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 6]
48. KV Pharmaceutical Company. A prospective, noninterventional follow-up study of children aged 23 to 25 months, born to mothers who received ydroxyprogesterone caproate injection, 250 mg/mL, or vehicle for prevention of preterm birth [ClinicalTrials.gov identifier NCT01146990]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 6]
49. KV Pharmaceutical Co. Ther-Rx corporation takes action to further ensure high-risk women are able to access FDα-approved makena ™ [media release]. 2011 May 31 [online]. Available from URL: http://www.kvph.com/news- center-article.aspx?articleid=341